肝硬度通过YAP/TAZ引导肝脏内胆固醇积累 在代谢功能障碍相关的脂肪性肝病中
Na Young Lee1, Myeung Gi Choi1, Ho Jae Ryu1
1College of Pharmacy, Seoul National University, Seoul, Republic of Korea.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|February 26, 2026
概括
与代谢功能障碍相关的脂肪性肝病 (MASLD) 中的肝硬性通过抑制肝 X 受体α (LXRα) 来驱动肝胆固醇的积累. 这种机器敏感通路会损害肝功能,并表明硬度是原因因素.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 肝硬度升高与代谢功能障碍相关的脂肪性肝病 (MASLD) 的不良结果有关.
- 肝硬性损害肝功能的确切机制尚不清楚.
研究的目的:
- 在MASLD中调查肝硬度和肝胆固醇水平之间的关系.
- 阐明将肝硬与胆固醇失调和肝细胞功能障碍联系起来的分子机制.
主要方法:
- 在人类MASLD队列和小鼠模型中对肝硬度和肝脏内胆固醇的相关性分析.
- 在体外研究中,使用单独的肝细胞来评估硬质基质上的胆固醇积累.
- 研究涉及YAP/TAZ和LXRα的机械敏感通路.
- 在小鼠中进行肝细胞特异性基因剥离研究.
- 对MASLD患者肝脏样本的转录组分析.
主要成果:
- 在人类和小鼠MASLD模型中,肝脏内胆固醇水平与肝硬度有很强的相关性.
- 刚性矩阵通过机械敏感地抑制肝脏X受体α (LXRα) 活性,促进胆固醇在肝细胞中的积累.
- 是的相关蛋白 (YAP) 和具有PDZ结合动机 (TAZ) 的转录协活性剂抑制了LXRα的激活,YAP干扰了LXRα/Retinoid X受体α (RXRα) 异构化.
- 在小鼠中,肝细胞特异的Yap/Taz切除改善了胆固醇排泄和减弱了纤维化进展.
- MASLD患者的肝脏转录组显示,LXRα标基因表达与肝硬度/YAP/TAZ活性之间存在逆相关性.
结论:
- 肝硬是MASLD肝胆固醇水平的一个决定因素.
- 由YAP/TAZ引起的LXRα硬性抑制是MASLD中驱动胆固醇失调和肝细胞功能障碍的关键机制.
- 针对肝硬度或YAP/TAZ-LXRα轴可能为MASLD提供治疗策略.
更多相关视频
相关概念视频
Cholesterol: Significance and Regulation
1.7K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
1.7K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.6K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
302
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
302
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
244
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
244
Liver Physiology
4.0K
The liver, an essential organ in the human body, performs over 200 vital functions that can be broadly categorized into metabolic, hematological, endocrine regulation, and bile production.
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
4.0K
Diseases of the Liver and Gallbladder
2.1K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.1K


